Final Diagnosis -- Recurrent Oligodendroglioma



1p and 19q are frequent events in gliomas and are proven to be predictors of chemotherapeutic response and prolonged survival in oligodendrogliomas. Patients with 1p/19q codeleted tumors have an overall survival of about 15 years with 4 years from first recurrence. Those without deletions had significantly lower survivals of 5 years and 12 months after first recurrence. The improved survival in patients with 1p/19q codeletion is significant when adjustments for age, tumor grade, and treatment are made [2]. Although 1p/19q codeletions and lack of EGFR amplification with negative p53 status define "genetically favorable" oligodendrogliomas [1], tumor progression and recurrence remain constant [2].


  1. Ohgaki, H. and P. Kleihues, Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol, 2005. 64(6): p. 479-89.
  2. Fallon, K.B., et al., Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol, 2004. 63(4): p. 314-22.

Contributed by Simon Chiosea, MD

Case IndexCME Case StudiesFeedbackHome